US2021087296A1PendingUtilityA1

Inhibitory antibodies and methods of use thereof

58
Assignee: UNIV CALIFORNIAPriority: Oct 3, 2016Filed: Dec 3, 2020Published: Mar 25, 2021
Est. expiryOct 3, 2036(~10.2 yrs left)· nominal 20-yr term from priority
Inventors:Xin GeDong Hyun NamTyler Lopez
C07K 2317/22C07K 2317/94C07K 2317/92C07K 2317/21C07K 2317/76C07K 2317/565C07K 2317/55A61K 2039/505A61P 35/00C07K 16/40
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Certain embodiments of the invention provide an antibody, or a fragment thereof, comprising a heavy chain complementarity-determining region 3 (CDR-H3) having at least about 80% sequence identity to a sequence described herein, as well as methods of use thereof.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An anti-MMP-14 antibody, or a fragment thereof, comprising:
 1) a heavy chain variable region (V H ) comprising a sequence having at least 90% sequence identity to SEQ ID NO:49; and a light chain variable region (V L ) comprising a sequence having at least 90% sequence identity to SEQ ID NO:50;   2) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:51; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:52;   3) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:53; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:54;   4) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:55; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:56;   5) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:57; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:58;   6) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:59; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:60;   7) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:63; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:64;   8) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:67; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:68;   9) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:69; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:70;   10) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:71; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:72;   11) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:73; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:74;   12) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:75; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:76;   13) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:77; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:78;   14) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:81; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:82;   15) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:89; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:90;   16) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:91; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:92;   17) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:93; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:94;   18) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:95; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:96;   19) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:97; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:98;   20) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:99; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:100;   21) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:101; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:102;   22) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:103; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:104;   23) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:105; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:106;   24) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:107; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:108;   25) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:111; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:112;   26) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:113; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:114;   27) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:115; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:116;   28) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:117; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:118; or   29) a V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:119; and a V L  comprising a sequence having at least 90% sequence identity to SEQ ID NO:120.   
     
     
         2 . The anti-MMP-14 antibody of  claim 1 , or a fragment thereof, wherein:
 1) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:49 comprises a heavy chain complementarity determining region 3 (CDR-H3) comprising a sequence having at least 90% sequence identity to SEQ ID NO:8;   2) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:51 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:11;   3) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:53 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:20;   4) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:55 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:14;   5) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:57 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:10;   6) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:59 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:9;   7) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:63 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:18;   8) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:67 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:15;   9) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:69 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:17;   10) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:71 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:16;   11) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:73 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:12;   12) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:75 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:13;   13) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:77 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:19;   14) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:81 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:21;   15) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:89 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:29;   16) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:91 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:30;   17) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:93 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:31;   18) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:95 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:32;   19) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:97 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:33;   20) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:99 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:34;   21) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:101 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:36;   22) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:103 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:37;   23) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:105 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:38;   24) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:107 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:39;   25) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:111 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:43;   26) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:113 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:44;   27) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:115 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:45;   28) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:117 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:46; or   29) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:119 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:47.   
     
     
         3 . The anti-MMP-14 antibody of  claim 1 , or a fragment thereof, wherein:
 1) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:49 comprises a heavy chain complementarity determining region 3 (CDR-H3) comprising SEQ ID NO:8;   2) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:51 comprises a CDR-H3 comprising SEQ ID NO:11;   3) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:53 comprises a CDR-H3 comprising SEQ ID NO:20;   4) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:55 comprises a CDR-H3 comprising SEQ ID NO:14;   5) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:57 comprises a CDR-H3 comprising SEQ ID NO:10;   6) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:59 comprises a CDR-H3 comprising SEQ ID NO:9;   7) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:63 comprises a CDR-H3 comprising SEQ ID NO:18;   8) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:67 comprises a CDR-H3 comprising SEQ ID NO:15;   9) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:69 comprises a CDR-H3 comprising SEQ ID NO:17;   10) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:71 comprises a CDR-H3 comprising SEQ ID NO:16;   11) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:73 comprises a CDR-H3 comprising SEQ ID NO:12;   12) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:75 comprises a CDR-H3 comprising SEQ ID NO:13;   13) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:77 comprises a CDR-H3 comprising SEQ ID NO:19;   14) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:81 comprises a CDR-H3 comprising SEQ ID NO:21;   15) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:89 comprises a CDR-H3 comprising SEQ ID NO:29;   16) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:91 comprises a CDR-H3 comprising SEQ ID NO:30;   17) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:93 comprises a CDR-H3 comprising SEQ ID NO:31;   18) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:95 comprises a CDR-H3 comprising SEQ ID NO:32;   19) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:97 comprises a CDR-H3 comprising SEQ ID NO:33;   20) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:99 comprises a CDR-H3 comprising SEQ ID NO:34;   21) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:101 comprises a CDR-H3 comprising SEQ ID NO:36;   22) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:103 comprises a CDR-H3 comprising SEQ ID NO:37;   23) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:105 comprises a CDR-H3 comprising SEQ ID NO:38;   24) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:107 comprises a CDR-H3 comprising SEQ ID NO:39;   25) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:111 comprises a CDR-H3 comprising SEQ ID NO:43;   26) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:113 comprises a CDR-H3 comprising SEQ ID NO:44;   27) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:115 comprises a CDR-H3 comprising SEQ ID NO:45;   28) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:117 comprises a CDR-H3 comprising SEQ ID NO:46; or   29) the V H  comprising a sequence having at least 90% sequence identity to SEQ ID NO:119 comprises a CDR-H3 comprising SEQ ID NO:47.   
     
     
         4 . The anti-MMP-14 antibody of  claim 1 , or a fragment thereof, comprising:
 1) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:49; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:50;   2) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:51; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:52;   3) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:53; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:54;   4) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:55; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:56;   5) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:57; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:58;   6) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:59; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:60;   7) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:63; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:64;   8) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:67; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:68;   9) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:69; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:70;   10) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:71; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:72;   11) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:73; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:74;   12) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:75; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:76;   13) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:77; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:78;   14) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:81; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:82;   15) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:89; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:90;   16) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:91; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:92;   17) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:93; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:94;   18) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:95; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:96;   19) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:97; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:98;   20) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:99; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:100;   21) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:101; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:102;   22) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:103; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:104;   23) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:105; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:106;   24) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:107; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:108;   25) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:111; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:112;   26) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:113; and a V L  comprising-a sequence having at least 95% sequence identity to SEQ ID NO:114;   27) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:115; and a V L  comprising-a sequence having at least 95% sequence identity to SEQ ID NO:116;   28) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:117; and a V L  comprising-a sequence having at least 95% sequence identity to SEQ ID NO:118; or   29) a V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:119; and a V L  comprising a sequence having at least 95% sequence identity to SEQ ID NO:120.   
     
     
         5 . The anti-MMP-14 antibody of  claim 4 , or a fragment thereof, wherein:
 1) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:49 comprises a heavy chain complementarity determining region 3 (CDR-H3) comprising a sequence having at least 90% sequence identity to SEQ ID NO:8;   2) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:51 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:11;   3) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:53 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:20;   4) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:55 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:14;   5) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:57 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:10;   6) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:59 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:9;   7) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:63 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:18;   8) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:67 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:15;   9) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:69 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:17;   10) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:71 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:16;   11) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:73 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:12;   12) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:75 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:13;   13) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:77 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:19;   14) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:81 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:21;   15) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:89 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:29;   16) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:91 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:30;   17) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:93 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:31;   18) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:95 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:32;   19) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:97 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:33;   20) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:99 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:34;   21) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:101 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:36;   22) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:103 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:37;   23) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:105 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:38;   24) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:107 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:39;   25) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:111 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:43;   26) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:113 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:44;   27) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:115 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:45;   28) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:117 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:46; or   29) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:119 comprises a CDR-H3 comprising a sequence having at least 90% sequence identity to SEQ ID NO:47.   
     
     
         6 . The anti-MMP-14 antibody of  claim 4 , or a fragment thereof, wherein:
 1) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:49 comprises a heavy chain complementarity determining region 3 (CDR-H3) comprising SEQ ID NO:8;   2) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:51 comprises a CDR-H3 comprising SEQ ID NO:11;   3) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:53 comprises a CDR-H3 comprising SEQ ID NO:20;   4) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:55 comprises a CDR-H3 comprising SEQ ID NO:14;   5) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:57 comprises a CDR-H3 comprising SEQ ID NO:10;   6) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:59 comprises a CDR-H3 comprising SEQ ID NO:9;   7) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:63 comprises a CDR-H3 comprising SEQ ID NO:18;   8) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:67 comprises a CDR-H3 comprising SEQ ID NO:15;   9) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:69 comprises a CDR-H3 comprising SEQ ID NO:17;   10) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:71 comprises a CDR-H3 comprising SEQ ID NO:16;   11) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:73 comprises a CDR-H3 comprising SEQ ID NO:12;   12) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:75 comprises a CDR-H3 comprising SEQ ID NO:13;   13) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:77 comprises a CDR-H3 comprising SEQ ID NO:19;   14) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:81 comprises a CDR-H3 comprising SEQ ID NO:21;   15) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:89 comprises a CDR-H3 comprising SEQ ID NO:29;   16) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:91 comprises a CDR-H3 comprising SEQ ID NO:30;   17) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:93 comprises a CDR-H3 comprising SEQ ID NO:31;   18) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:95 comprises a CDR-H3 comprising SEQ ID NO:32;   19) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:97 comprises a CDR-H3 comprising SEQ ID NO:33;   20) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:99 comprises a CDR-H3 comprising SEQ ID NO:34;   21) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:101 comprises a CDR-H3 comprising SEQ ID NO:36;   22) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:103 comprises a CDR-H3 comprising SEQ ID NO:37;   23) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:105 comprises a CDR-H3 comprising SEQ ID NO:38;   24) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:107 comprises a CDR-H3 comprising SEQ ID NO:39;   25) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:111 comprises a CDR-H3 comprising SEQ ID NO:43;   26) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:113 comprises a CDR-H3 comprising SEQ ID NO:44;   27) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:115 comprises a CDR-H3 comprising SEQ ID NO:45;   28) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:117 comprises a CDR-H3 comprising SEQ ID NO:46; or   29) the V H  comprising a sequence having at least 95% sequence identity to SEQ ID NO:119 comprises a CDR-H3 comprising SEQ ID NO:47.   
     
     
         7 . The anti-MMP-14 antibody of  claim 1 , or a fragment thereof, comprising:
 1) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:49; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:50;   2) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:51; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:52;   3) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:53; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:54;   4) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:55; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:56;   5) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:57; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:58;   6) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:59; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:60;   7) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:63; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:64;   8) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:67; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:68;   9) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:69; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:70;   10) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:71; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:72;   11) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:73; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:74;   12) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:75; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:76;   13) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:77; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:78;   14) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:81; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:82;   15) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:89; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:90;   16) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:91; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:92;   17) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:93; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:94;   18) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:95; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:96;   19) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:97; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:98;   20) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:99; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:100;   21) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:101; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:102;   22) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:103; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:104;   23) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:105; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:106;   24) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:107; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:108;   25) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:111; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:112;   26) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:113; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:114;   27) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:115; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:116;   28) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:117; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:118; or   29) a V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:119; and a V L  comprising a sequence having at least 97% sequence identity to SEQ ID NO:120.   
     
     
         8 . The anti-MMP-14 antibody of  claim 7 , or a fragment thereof, wherein:
 1) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:49 comprises a heavy chain complementarity determining region 3 (CDR-H3) comprising SEQ ID NO:8;   2) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:51 comprises a CDR-H3 comprising SEQ ID NO:11;   3) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:53 comprises a CDR-H3 comprising SEQ ID NO:20;   4) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:55 comprises a CDR-H3 comprising SEQ ID NO:14;   5) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:57 comprises a CDR-H3 comprising SEQ ID NO:10;   6) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:59 comprises a CDR-H3 comprising SEQ ID NO:9;   7) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:63 comprises a CDR-H3 comprising SEQ ID NO:18;   8) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:67 comprises a CDR-H3 comprising SEQ ID NO:15;   9) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:69 comprises a CDR-H3 comprising SEQ ID NO:17;   10) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:71 comprises a CDR-H3 comprising SEQ ID NO:16;   11) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:73 comprises a CDR-H3 comprising SEQ ID NO:12;   12) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:75 comprises a CDR-H3 comprising SEQ ID NO:13;   13) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:77 comprises a CDR-H3 comprising SEQ ID NO:19;   14) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:81 comprises a CDR-H3 comprising SEQ ID NO:21;   15) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:89 comprises a CDR-H3 comprising SEQ ID NO:29;   16) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:91 comprises a CDR-H3 comprising SEQ ID NO:30;   17) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:93 comprises a CDR-H3 comprising SEQ ID NO:31;   18) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:95 comprises a CDR-H3 comprising SEQ ID NO:32;   19) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:97 comprises a CDR-H3 comprising SEQ ID NO:33;   20) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:99 comprises a CDR-H3 comprising SEQ ID NO:34;   21) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:101 comprises a CDR-H3 comprising SEQ ID NO:36;   22) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:103 comprises a CDR-H3 comprising SEQ ID NO:37;   23) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:105 comprises a CDR-H3 comprising SEQ ID NO:38;   24) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:107 comprises a CDR-H3 comprising SEQ ID NO:39;   25) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:111 comprises a CDR-H3 comprising SEQ ID NO:43;   26) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:113 comprises a CDR-H3 comprising SEQ ID NO:44;   27) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:115 comprises a CDR-H3 comprising SEQ ID NO:45;   28) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:117 comprises a CDR-H3 comprising SEQ ID NO:46; or   29) the V H  comprising a sequence having at least 97% sequence identity to SEQ ID NO:119 comprises a CDR-H3 comprising SEQ ID NO:47.   
     
     
         9 . The anti-MMP-14 antibody of  claim 1 , or a fragment thereof, comprising:
 1) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:49; and a V L  comprising-a sequence having at least 99% sequence identity to SEQ ID NO:50;   2) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:51; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:52;   3) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:53; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:54;   4) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:55; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:56;   5) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:57; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:58;   6) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:59; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:60;   7) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:63; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:64;   8) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:67; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:68;   9) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:69; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:70;   10) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:71; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:72;   11) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:73; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:74;   12) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:75; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:76;   13) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:77; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:78;   14) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:81; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:82;   15) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:89; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:90;   16) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:91; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:92;   17) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:93; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:94;   18) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:95; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:96;   19) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:97; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:98;   20) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:99; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:100;   21) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:101; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:102;   22) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:103; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:104;   23) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:105; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:106;   24) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:107; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:108;   25) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:111; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:112;   26) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:113; and a V L  comprising-a sequence having at least 99% sequence identity to SEQ ID NO:114;   27) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:115; and a V L  comprising-a sequence having at least 99% sequence identity to SEQ ID NO:116;   28) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:117; and a V L  comprising-a sequence having at least 99% sequence identity to SEQ ID NO:118; or   29) a V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:119; and a V L  comprising a sequence having at least 99% sequence identity to SEQ ID NO:120.   
     
     
         10 . The anti-MMP-14 antibody of  claim 9 , or a fragment thereof, wherein:
 1) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:49 comprises a heavy chain complementarity determining region 3 (CDR-H3) comprising SEQ ID NO:8;   2) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:51 comprises a CDR-H3 comprising SEQ ID NO:11;   3) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:53 comprises a CDR-H3 comprising SEQ ID NO:20;   4) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:55 comprises a CDR-H3 comprising SEQ ID NO:14;   5) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:57 comprises a CDR-H3 comprising SEQ ID NO:10;   6) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:59 comprises a CDR-H3 comprising SEQ ID NO:9;   7) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:63 comprises a CDR-H3 comprising SEQ ID NO:18;   8) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:67 comprises a CDR-H3 comprising SEQ ID NO:15;   9) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:69 comprises a CDR-H3 comprising SEQ ID NO:17;   10) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:71 comprises a CDR-H3 comprising SEQ ID NO:16;   11) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:73 comprises a CDR-H3 comprising SEQ ID NO:12;   12) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:75 comprises a CDR-H3 comprising SEQ ID NO:13;   13) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:77 comprises a CDR-H3 comprising SEQ ID NO:19;   14) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:81 comprises a CDR-H3 comprising SEQ ID NO:21;   15) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:89 comprises a CDR-H3 comprising SEQ ID NO:29;   16) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:91 comprises a CDR-H3 comprising SEQ ID NO:30;   17) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:93 comprises a CDR-H3 comprising SEQ ID NO:31;   18) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:95 comprises a CDR-H3 comprising SEQ ID NO:32;   19) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:97 comprises a CDR-H3 comprising SEQ ID NO:33;   20) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:99 comprises a CDR-H3 comprising SEQ ID NO:34;   21) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:101 comprises a CDR-H3 comprising SEQ ID NO:36;   22) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:103 comprises a CDR-H3 comprising SEQ ID NO:37;   23) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:105 comprises a CDR-H3 comprising SEQ ID NO:38;   24) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:107 comprises a CDR-H3 comprising SEQ ID NO:39;   25) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:111 comprises a CDR-H3 comprising SEQ ID NO:43;   26) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:113 comprises a CDR-H3 comprising SEQ ID NO:44;   27) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:115 comprises a CDR-H3 comprising SEQ ID NO:45;   28) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:117 comprises a CDR-H3 comprising SEQ ID NO:46; or   29) the V H  comprising a sequence having at least 99% sequence identity to SEQ ID NO:119 comprises a CDR-H3 comprising SEQ ID NO:47.   
     
     
         11 . The anti-MMP-14 antibody, or fragment thereof, of  claim 1 , which is an inhibitor of MMP-14. 
     
     
         12 . The anti-MMP-14 antibody, or fragment thereof, of  claim 11 , which is a selective inhibitor of MMP-14. 
     
     
         13 . The anti-MMP-14 antibody, or fragment thereof, of  claim 1 , which comprises a convex shaped paratope. 
     
     
         14 . The anti-MMP-14 antibody, or fragment thereof, of  claim 1 , which is an antibody fragment. 
     
     
         15 . The anti-MMP-14 antibody, or fragment thereof, of  claim 1 , which is a Fab, F(ab′)2, Fv, single-chain Fv (scFv), diabody (diabodies), linear antibody or a multispecific antibody prepared from an antibody fragment. 
     
     
         16 . A composition comprising an anti-MMP-14 antibody, or fragment thereof, as described in  claim 1  and physiologically-acceptable, non-toxic carrier. 
     
     
         17 . The composition of  claim 16 , which is a pharmaceutical composition, wherein the carrier is a pharmaceutically acceptable carrier. 
     
     
         18 . A kit comprising an anti-MMP-14 antibody, or a fragment thereof, as described in  claim 1 , packaging material, and instructions for administering the antibody, or a fragment thereof, to a mammal.

Join the waitlist — get patent alerts

Track US2021087296A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.